On 12 November Otonomy, Inc. (NASDAQ:OTIC) reported financial results for the third quarter ended September 30, 2014. Cash totaled $165.2 million as of September 30, 2014, compared with $37.3 million as of December 31, 2013. Otonomy, Inc. (NASDAQ:OTIC) in last trading activity increased 9.67% to close at $35.38. Company weekly performance is 22.04% while its quarterly performance stands at 82.37%. Otonomy, Inc. (NASDAQ:OTIC) is 5.17% away from its 52 week high.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible Preferred Stock (the “Series E Preferred Stock”). The quarterly dividend on the Series E Preferred Stock is payable on January 2, 2015 to holders of record at the close of business on December 19, 2014. On last trading day Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) advanced 0.68% to close at $1.49. Its volatility for the week is 6.37% while volatility for the month is 4.16%. PPHM’s sales growth for past 5 years was 4.20% and its EPS growth for past 5 years was 9.90%. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) monthly performance is 0.68%.
Northrim Bancorp Inc (NASDAQ:NRIM) announced a quarterly dividend. Shareholders of record on Thursday, December 11th will be paid a dividend of 0.18 per share on Friday, December 19th. This represents a $0.72 annualized dividend and a dividend yield of 2.64%. On last trading day Northrim Bancorp Inc. (NASDAQ:NRIM) moved down -2.02% to close at $27.67. Its volatility for the week is 2.73% while volatility for the month is 2.33%. NRIM’s sales growth for past 5 years was -5.00% and its EPS growth for past 5 years was 14.40%. Northrim Bancorp Inc. (NASDAQ:NRIM) monthly performance is -4.59%.
On 14 November Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) reported unaudited third quarter fiscal year 2014 earnings, for the period ended September 30, 2014. First nine months 2014 revenue totaled $39.4 million up 20.0% from $32.9 million. Gross margin of 45.5% for the first nine months of fiscal 2014 as compared to 51%. Skystar Bio Pharmaceutical Company (NASDAQ:SKBI) has 46.90% insider ownership while its institutional ownership stands at 20.70%. In last trading activity company’s stock closed at $4.63.
On 17 November pSivida Corp. (NASDAQ:PSDV) announced that the Irish Health Products Regulatory Authority (HPRA) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. This marks the 13th country in which ILUVIEN has been approved for commercialization. On Wednesday shares of pSivida Corp. (NASDAQ:PSDV) closed at $4.52. Company’s sales growth for last 5 years was -22.10%